Kymera raises $65M from global syndicate as it aims for the clinic with protein degradation tech
You can add Kymera Therapeutics to the list of biotechs attracting attention from an international set of investors.
The biotech is taking the lid off …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
